Teva Pharma (NYSE: TEVA) and Active Biotech announced that the patient enrollment for the pivotal Phase III CONCERTO trial has ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE